Seaport and Hemab Target $180m IPOs as Biotech Listings Accumulate

Why It Matters

The raises give both companies runway to push late‑stage candidates toward commercialization, underscoring renewed investor appetite for high‑growth biotech pipelines despite broader market volatility.

Key Takeaways

• Seaport aims to raise $183.5 m, midpoint pricing $17 per share
• Hemab targets $180.3 m net proceeds, offering 11.7 m shares
• GlyphAllo will receive ~ $121 m for Phase IIb/III trials
• Hemab allocates $120 m to develop sutacimig for bleeding disorders
• Biotech IPOs have raised over $1.5 bn this year, signaling market resilience

Pulse Analysis

The Nasdaq has become a hotbed for biotech capital this quarter, with Seaport Therapeutics and Hemab Therapeutics each filing prospectuses that could net close to $180 million. Their pricing bands of $16‑$18 per share mirror a broader trend where investors are willing to back companies that have de‑risked their pipelines through early‑stage data. By stacking their offerings in the same week, the two firms reinforce a narrative that the sector is regaining momentum after a slowdown in 2025, and that capital is flowing toward differentiated therapeutic approaches.

Seaport’s flagship program, GlyphAllo, leverages a novel lymphatic delivery platform designed to improve oral bioavailability of neurosteroid‑based treatments. The $121 million earmarked for GlyphAllo will fund a Phase IIb trial and propel the candidate into Phase III, positioning the company to compete with injectable options like Zulresso. If successful, the oral formulation could capture a sizable share of the major depressive disorder market, estimated at over $10 billion globally, while also expanding into anxiety and other neuropsychiatric indications. The allocation of remaining proceeds to ancillary assets further diversifies Seaport’s risk profile.

Hemab’s lead asset, sutacimig, is a bispecific antibody targeting rare bleeding disorders such as Glanzmann thrombasthenia and Factor VII deficiency. With roughly $120 million dedicated to its clinical development, Hemab aims to fill a niche where few therapies exist, potentially commanding premium pricing. An additional $60 million will support its pipeline expansion, including HMB‑002 for von Willebrand disease. The strong cash balance at year‑end and the sizable IPO proceeds suggest Hemab can sustain multi‑year development without dilutive financing, a factor that investors watch closely. Together, these offerings illustrate how biotech firms are using public markets to fund late‑stage trials, signaling confidence in the sector’s growth trajectory despite macroeconomic headwinds.

Deal Summary

Seaport Therapeutics and Hemab Therapeutics announced Nasdaq IPO pricing, each offering roughly 11.8M and 11.7M shares at $16‑$18 per share, respectively. The companies expect net proceeds of about $183.5M and $180.3M, for a combined raise of roughly $364M, adding to a busy biotech listing season.